HCC in peri-transplant period: What a gastroenterologist needs to know.
作者信息
Rabiee Atoosa, Miller Jennifer B
机构信息
Veterans Affairs Medical Center and Hunter Holmes McGuire Richmond VA Medical Center, Washington, DC, USA.
出版信息
Clin Liver Dis (Hoboken). 2023 Jul 7;22(1):7-9. doi: 10.1097/CLD.0000000000000071. eCollection 2023 Jul.
Abstract
摘要
相似文献
1
HCC in peri-transplant period: What a gastroenterologist needs to know.肝移植围手术期的肝细胞癌：胃肠病学家需要了解的内容。
Clin Liver Dis (Hoboken). 2023 Jul 7;22(1):7-9. doi: 10.1097/CLD.0000000000000071. eCollection 2023 Jul.
2
Management of the Cirrhotic Patient Before Liver Transplantation: The Role of the Referring Gastroenterologist.肝移植前肝硬化患者的管理：转诊胃肠病学家的作用。
Gastroenterol Hepatol (N Y). 2006 May;2(5):346-354.
3
CT colonography: what the gastroenterologist needs to know.CT结肠成像：胃肠病学家需要了解的内容。
Frontline Gastroenterol. 2011 Apr;2(2):96-104. doi: 10.1136/fg.2009.000380. Epub 2011 Feb 16.
4
Utilization of Immunotherapy for the Treatment of Hepatocellular Carcinoma in the Peri-Transplant Setting: Transplant Oncology View.免疫疗法在肝移植围手术期治疗肝细胞癌中的应用：移植肿瘤学视角
Cancers (Basel). 2022 Mar 30;14(7):1760. doi: 10.3390/cancers14071760.
5
Strongyloidiasis: what every gastroenterologist needs to know.类圆线虫病：每位胃肠病学家都需要了解的知识。
Ther Adv Chronic Dis. 2022 Nov 15;13:20406223221137499. doi: 10.1177/20406223221137499. eCollection 2022.
6
Practical Management of HRS-AKI in the Era of Terlipressin: What the Gastroenterologist Needs to Know.特利加压素时代肝肾综合征-急性肾损伤的实际管理：胃肠病学家需要了解的内容。
Am J Gastroenterol. 2023 Jun 1;118(6):915-920. doi: 10.14309/ajg.0000000000002115. Epub 2023 Jan 23.
7
Impact of peri-transplant heart failure & left-ventricular diastolic dysfunction on outcomes following liver transplantation.肝移植后移植前心力衰竭和左心室舒张功能障碍对结局的影响。
Liver Int. 2012 Sep;32(8):1262-9. doi: 10.1111/j.1478-3231.2012.02818.x. Epub 2012 May 24.
8
Patient experience surveys: what every gastroenterologist needs to know.
Clin Gastroenterol Hepatol. 2013 Dec;11(12):1529-31. doi: 10.1016/j.cgh.2013.09.026.
9
Pre-transplant therapy for hepatocellular carcinoma is associated with a lower recurrence after liver transplantation.肝移植前治疗肝癌可降低肝移植后的复发率。
Clin Transplant. 2009 Nov-Dec;23(6):874-81. doi: 10.1111/j.1399-0012.2009.00993.x. Epub 2009 May 4.
10
A method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting list.一种在共同的肝移植等待名单上为肝癌患者和非肝癌患者分配公平性的方法。
J Hepatol. 2014 Feb;60(2):290-7. doi: 10.1016/j.jhep.2013.10.010. Epub 2013 Oct 23.
引用本文的文献
1
Proper assessment and prognostication of patients with hepatocellular carcinoma.肝细胞癌患者的正确评估与预后判断
Clin Liver Dis (Hoboken). 2024 Mar 7;23(1):e0129. doi: 10.1097/CLD.0000000000000129. eCollection 2024 Jan-Jun.
本文引用的文献
1
The Impact of Median Model for End-Stage Liver Disease at Transplant Minus 3 National Policy on Waitlist Outcomes in Patients With and Without Hepatocellular Carcinoma.终末期肝病模型中位数在移植减去 3 全国政策对伴有和不伴有肝细胞癌患者等候名单结果的影响。
Liver Transpl. 2022 Mar;28(3):376-385. doi: 10.1002/lt.26368. Epub 2021 Dec 8.
2
Provider Attitudes Toward Risk-Based Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis in the United States.美国肝硬化患者基于风险的肝细胞癌监测的提供者态度。
Clin Gastroenterol Hepatol. 2022 Jan;20(1):183-193. doi: 10.1016/j.cgh.2020.09.015. Epub 2020 Sep 12.
3
Liver transplantation for hepatocellular carcinoma: Management after the transplant.肝移植治疗肝细胞癌：移植后的管理。
Am J Transplant. 2020 Feb;20(2):333-347. doi: 10.1111/ajt.15697. Epub 2019 Dec 9.
4
Model for end-stage liver disease exception points for treatment-responsive hepatocellular carcinoma.治疗反应性肝细胞癌的终末期肝病模型例外点
Clin Liver Dis (Hoboken). 2016 May 27;7(5):97-100. doi: 10.1002/cld.545. eCollection 2016 May.
5
Liver Allocation Policies in the USA: Past, Present, and the Future.美国的肝脏分配政策：过去、现在和未来。
Dig Dis Sci. 2019 Apr;64(4):985-992. doi: 10.1007/s10620-019-05549-y.
6
Are There Upper Limits in Tumor Burden for Down-Staging of Hepatocellular Carcinoma to Liver Transplant? Analysis of the All-Comers Protocol.肝癌降期至肝移植的肿瘤负担是否存在上限？全人群方案分析。
Hepatology. 2019 Oct;70(4):1185-1196. doi: 10.1002/hep.30570. Epub 2019 Apr 12.
7
Validation of the prognostic power of the RETREAT score for hepatocellular carcinoma recurrence using the UNOS database.利用 UNOS 数据库验证 RETREAT 评分对肝细胞癌复发预后的预测能力。
Am J Transplant. 2018 May;18(5):1206-1213. doi: 10.1111/ajt.14549. Epub 2017 Dec 2.
8
Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial.西罗莫司在肝细胞癌肝移植受者中的应用：一项随机、多中心、开放标签的3期试验。
Transplantation. 2016 Jan;100(1):116-25. doi: 10.1097/TP.0000000000000965.
9
Managements of recurrent hepatocellular carcinoma after liver transplantation: A systematic review.肝移植术后复发性肝细胞癌的管理：一项系统综述。
World J Gastroenterol. 2015 Oct 21;21(39):11185-98. doi: 10.3748/wjg.v21.i39.11185.
10
Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence.钙调神经磷酸酶抑制剂治疗下的肝细胞癌肝移植：肿瘤复发危险因素的重新评估
Ann Surg. 2008 Nov;248(5):857-62. doi: 10.1097/SLA.0b013e3181896278.
Zotero 插件